Search Results for "vitamin D"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vitamin D. Results 21 to 27 of 27 total matches.
Drugs for Age-Related Macular Degeneration
The Medical Letter on Drugs and Therapeutics • Jan 06, 2025 (Issue 1719)
is
caused by wet AMD.1
DRY AMD
SUPPLEMENTS — Various oral vitamin and mineral
supplements are promoted ...
Age-related macular degeneration (AMD) has two
major forms: dry or non-neovascular (~90% of
patients) and wet or neovascular (~10% of patients).
Med Lett Drugs Ther. 2025 Jan 6;67(1719):1-5 doi:10.58347/tml.2025.1719a | Show Introduction Hide Introduction
Drugs for Epilepsy
The Medical Letter on Drugs and Therapeutics • Aug 05, 2024 (Issue 1708)
. Serum folic acid, thyroxine, and vitamin K concentrations may decrease with long-term therapy ...
When used for the appropriate seizure type,
antiseizure medications (ASMs) are roughly
equivalent in efficacy. In addition to the seizure type,
the choice of drug is usually based on factors such
as ease of use, spectrum of activity, adverse effects,
interactions with other drugs, presence of comorbid
conditions, suitability for elderly persons and those
with childbearing potential, and cost. Treatment
should begin with a single drug, increasing the
dosage gradually until seizures are controlled or
adverse effects become unacceptable. If seizures
persist, expert clinicians generally...
Med Lett Drugs Ther. 2024 Aug 5;66(1708):121-8 doi:10.58347/tml.2024.1708a | Show Introduction Hide Introduction
Lipid-Lowering Drugs
The Medical Letter on Drugs and Therapeutics • Sep 19, 2022 (Issue 1659)
with a PCSK9 inhibitor can result in very
low LDL-C levels ( ...
Cholesterol management guidelines from the
American College of Cardiology/American Heart
Association Task Force were last published in 2019.
Drugs for Irritable Bowel Syndrome
The Medical Letter on Drugs and Therapeutics • Feb 03, 2025 (Issue 1721)
by bloating.1-4 IBS
is classified by its predominant bowel symptom:
constipation (IBS-C), diarrhea (IBS-D ...
Irritable bowel syndrome (IBS) is a common disorder
characterized by recurrent abdominal pain and altered
bowel habits, often accompanied by bloating. IBS
is classified by its predominant bowel symptom:
constipation (IBS-C), diarrhea (IBS-D), mixed type
(IBS-M), or unclassified (IBS-U). Since the exact cause
of IBS is unknown, the goal of treatment is symptom
control. Some over-the-counter (OTC) products and
prescription drugs for IBS are listed in Tables 1-4. The
safety of these drugs during pregnancy and lactation
is described in Table 5 (online only).
Med Lett Drugs Ther. 2025 Feb 3;67(1721):17-24 doi:10.58347/tml.2025.1721a | Show Introduction Hide Introduction
Drugs for Bipolar Disorder
The Medical Letter on Drugs and Therapeutics • Apr 01, 2024 (Issue 1699)
of major malformations and vitamin K
deficiency, which can lead to neonatal hemorrhage.
Data on use ...
Bipolar disorder is characterized by episodes of
mania, hypomania, and depression. Recurrences of
manic or (more frequently) depressive symptoms
are common. About 15-20% of patients with bipolar
disorder die by suicide.
Med Lett Drugs Ther. 2024 Apr 1;66(1699):49-54 doi:10.58347/tml.2024.1699a | Show Introduction Hide Introduction
Drugs for GERD and Peptic Ulcer Disease
The Medical Letter on Drugs and Therapeutics • Apr 04, 2022 (Issue 1647)
. Should be taken on an empty stomach.
including dementia, vitamin B12 deficiency, chronic
kidney disease ...
Gastroesophageal reflux disease (GERD) is the most
common GI condition encountered in the outpatient
setting; it affects about 20% of people in the US.
Noninsulin Drugs for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Nov 24, 2025 (Issue 1742)
(metallic taste, nausea, diarrhea, abdominal
pain), vitamin B12 deficiency, and (rarely) lactic
acidosis ...
Diet, exercise, and weight loss can improve glycemic
control, but most patients with type 2 diabetes
eventually require glucose-lowering pharmacotherapy.
An A1C goal of <7% (while minimizing hypoglycemia)
is recommended for most patients to prevent or
reduce the microvascular complications of diabetes
(retinopathy, nephropathy, neuropathy). An A1C target
of <8% may be appropriate for patients who are older,
have comorbid conditions, or are at risk of serious
hypoglycemia-associated adverse events.
Med Lett Drugs Ther. 2025 Nov 24;67(1742):185-92 doi:10.58347/tml.2025.1742a | Show Introduction Hide Introduction
